Spokane, Wash.-based biotech startup Iasis Molecular Sciences received a $1.25 million grant from a U.S. government program that addresses spinal cord injuries. The 7-year old company will develop a “wholly antimicrobial” urinary catheter that incorporates the company’s proprietary antimicrobials throughout its structure, instead of just as a coating. Founder and CEO David Vachon, an organic chemist, won the grant with the support of the Health Sciences and Services Authority of Spokane County, a Washington-state funded initiative that provides up to $500,000 in matching funds.
News Brief
